IBDEI1XU ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30953,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,30953,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,30953,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,30954,0)
 ;;=E10.22^^123^1598^16
 ;;^UTILITY(U,$J,358.3,30954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30954,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,30954,1,4,0)
 ;;=4^E10.22
 ;;^UTILITY(U,$J,358.3,30954,2)
 ;;=^5002590
 ;;^UTILITY(U,$J,358.3,30955,0)
 ;;=D59.3^^123^1598^3
 ;;^UTILITY(U,$J,358.3,30955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30955,1,3,0)
 ;;=3^Hemolytic-uremic syndrome
 ;;^UTILITY(U,$J,358.3,30955,1,4,0)
 ;;=4^D59.3
 ;;^UTILITY(U,$J,358.3,30955,2)
 ;;=^55823
 ;;^UTILITY(U,$J,358.3,30956,0)
 ;;=D69.0^^123^1598^4
 ;;^UTILITY(U,$J,358.3,30956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30956,1,3,0)
 ;;=3^Henoch-Schoeniein Purpura
 ;;^UTILITY(U,$J,358.3,30956,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,30956,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,30957,0)
 ;;=M30.0^^123^1598^12
 ;;^UTILITY(U,$J,358.3,30957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30957,1,3,0)
 ;;=3^Polyarteritis nodosa
 ;;^UTILITY(U,$J,358.3,30957,1,4,0)
 ;;=4^M30.0
 ;;^UTILITY(U,$J,358.3,30957,2)
 ;;=^5011738
 ;;^UTILITY(U,$J,358.3,30958,0)
 ;;=M31.0^^123^1598^5
 ;;^UTILITY(U,$J,358.3,30958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30958,1,3,0)
 ;;=3^Hypersensitivity angiitis
 ;;^UTILITY(U,$J,358.3,30958,1,4,0)
 ;;=4^M31.0
 ;;^UTILITY(U,$J,358.3,30958,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,30959,0)
 ;;=M31.31^^123^1598^22
 ;;^UTILITY(U,$J,358.3,30959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30959,1,3,0)
 ;;=3^Wegener's granulomatosis w/ renal involvement
 ;;^UTILITY(U,$J,358.3,30959,1,4,0)
 ;;=4^M31.31
 ;;^UTILITY(U,$J,358.3,30959,2)
 ;;=^5011745
 ;;^UTILITY(U,$J,358.3,30960,0)
 ;;=N28.89^^123^1598^6
 ;;^UTILITY(U,$J,358.3,30960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30960,1,3,0)
 ;;=3^Kidney & Ureter Disorders,Oth Specified
 ;;^UTILITY(U,$J,358.3,30960,1,4,0)
 ;;=4^N28.89
 ;;^UTILITY(U,$J,358.3,30960,2)
 ;;=^88007
 ;;^UTILITY(U,$J,358.3,30961,0)
 ;;=E85.4^^123^1598^11
 ;;^UTILITY(U,$J,358.3,30961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30961,1,3,0)
 ;;=3^Organ-limited amyloidosis
 ;;^UTILITY(U,$J,358.3,30961,1,4,0)
 ;;=4^E85.4
 ;;^UTILITY(U,$J,358.3,30961,2)
 ;;=^5003017
 ;;^UTILITY(U,$J,358.3,30962,0)
 ;;=M32.14^^123^1598^2
 ;;^UTILITY(U,$J,358.3,30962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30962,1,3,0)
 ;;=3^Glomerular disease in systemic lupus erythematosus
 ;;^UTILITY(U,$J,358.3,30962,1,4,0)
 ;;=4^M32.14
 ;;^UTILITY(U,$J,358.3,30962,2)
 ;;=^5011757
 ;;^UTILITY(U,$J,358.3,30963,0)
 ;;=M32.15^^123^1598^15
 ;;^UTILITY(U,$J,358.3,30963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30963,1,3,0)
 ;;=3^Tubulo-interstitial neuropathy in SLE
 ;;^UTILITY(U,$J,358.3,30963,1,4,0)
 ;;=4^M32.15
 ;;^UTILITY(U,$J,358.3,30963,2)
 ;;=^5011758
 ;;^UTILITY(U,$J,358.3,30964,0)
 ;;=M34.0^^123^1598^13
 ;;^UTILITY(U,$J,358.3,30964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30964,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,30964,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,30964,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,30965,0)
 ;;=M31.1^^123^1598^14
 ;;^UTILITY(U,$J,358.3,30965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30965,1,3,0)
 ;;=3^Thrombotic Microangiopathy
